Multitargeted therapy: Can promiscuity be praised in an era of political correctness?

Antonio Jimeno, Manuel Hidalgo

Research output: Contribution to journalReview articlepeer-review

Abstract

The rapidly expanding knowledge of the pathogenesis of cancer at the molecular level is providing new targets for drug discovery and development. However, cancer is a complex disease characterized by multiple genetic and molecular alterations affecting cell proliferation, survival, differentiation and invasion among others. Many of these alterations represent potential targets for the development of new anticancer therapeutics. Because of the enormous biological diversity of cancer, it is unlikely that attacking only one of these targets will eliminate a malignant cell. Rather, strategic combination of agents targeted against the most critical of those alterations will be needed. Another approach that is rendering promising clinical results is the use of more unspecific agents that inhibit or modulate several relevant targets simultaneously. A deep biologic understanding of the relative relevance of each target in different cancer types will be key to efficiently direct those drugs to diseases more likely to benefit from its particular modulation profile.

Original languageEnglish (US)
Pages (from-to)150-158
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume59
Issue number2
DOIs
StatePublished - Aug 2006

Keywords

  • Dual targeting
  • EGFR
  • MAPK
  • Promiscuous agents
  • Targeted therapies

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Multitargeted therapy: Can promiscuity be praised in an era of political correctness?'. Together they form a unique fingerprint.

Cite this